• Ryosuke Nakatsubo, Yoshiya Yamauchi, Taisho Hiraizumi, Fumi Naruse, Ryoya Kanda, Yuka Suzuki, Tatsuya Kakegawa, Takashi Kurosawa, Yu Yoshimasu, Toru Saguchi, Atsushi Sofuni, and Takao Itoi.
• Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.
• Medicine (Baltimore). 2021 Jul 16; 100 (28): e26651e26651.

RationaleHypersplenism causes thrombocytopenia, which may lead to the reduction or discontinuation of chemotherapy. Partial splenic embolization (PSE) is an effective treatment for thrombocytopenia associated with hypersplenism. However, there have been no reports of patients with gastric cancer who have resumed and continued chemotherapy after PSE for splenic hypersplenism associated with tumor infiltration.Here, we report two cases in which we performed PSE for hypersplenism associated with gastric cancer that had invaded the splenic vein. Chemotherapy was continued in both cases.Patient ConcernsBoth patients developed thrombocytopenia with splenomegaly due to advanced gastric cancer that required discontinuation of chemotherapy.DiagnosisUpper gastrointestinal endoscopy and computed tomography showed advanced gastric cancer with invasion of the splenic vein and splenomegaly. Both patients developed thrombocytopenia.InterventionsPatients were treated with PSE.OutcomesPSE produced an increase in thrombocyte count, and chemotherapy could be resumed.LessonsPSE seems to be a useful treatment for thrombocytopenia with splenomegaly associated with advanced gastric cancer and may allow continuation of chemotherapy.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

19 keywords...

hide…